So you are admitting that they need to "bypass" the FDA. Very interesting. I agree that the results of clinical trials to date have been inconclusive on Ropren.
Proper clinical trials that show no statistically significant positive effect for Ropren would be very damaging, so I agree that doing a full Phase III trial could be extremely hazardous to the Solagran share price. Best to keep the dodgy stuff in Russia.
- Forums
- ASX - By Stock
- SLA
- wait before topping up
wait before topping up, page-35
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
Previous Video
Next Video
SPONSORED BY The Market Online